251. Ganglioside and Growth Factor Interactions Promote Mesencephalic Cell Survival from the Excitotoxic Actions of 2,4,5-Trihydroxyphenylalanine
- Author
-
Stephen D. Skaper, Laura Facci, and R Dal Toso
- Subjects
Agonist ,Levodopa ,medicine.drug_class ,Central nervous system ,Dopaminergic ,Striatum ,Biology ,Pharmacology ,Neuroprotection ,Glutamatergic ,medicine.anatomical_structure ,Dopamine ,medicine ,Neuroscience ,medicine.drug - Abstract
Publisher Summary This chapter discusses how ganglioside and growth factor interactions promote mesencephalic cell survival from the excitotoxic actions of 2,4,5-trihydroxyphenylalanine. The observation that Parkinson's disease (PD) is associated with a marked reduction of dopamine content in the corpus striatum forms the therapeutic rationale for the utilization of drugs, such as levodopa (L-dopa), to affect an increase in striatal dopamine content. However, the chronic treatment of PD patients with L-dopa can also elicit negative side effects such as the on-off phenomena as well as an increase in the levels of potentially toxic oxidation metabolites of L-dopa and dopamine. In a study, the 6-hydroxylated derivative of dopa (2,4,5-trihydroxyphenylalanine or TOPA) has been shown to act as a glutamatergic agonist selective for non-N-methyl- d -aspartate (NMDA) receptors eliciting both electrophysiological and neurotoxic effects on central nervous system (CNS) neurons typical of excitatory amino acids (EAA). The results with GM1 on TOPA-treated mesencephallic cultures, together with other indications for its effective neuroplastic and/or neuroprotective actions in CNS models of dopaminergic damage, indicate that GM1 may be a possible candidate to apply in animal models exposed to acute or chronic TOPA toxicity.
- Published
- 1994
- Full Text
- View/download PDF